0.791
-0.01 (-0.63%)
| Penutupan Terdahulu | 0.796 |
| Buka | 0.841 |
| Jumlah Dagangan | 1,018,705 |
| Purata Dagangan (3B) | 673,703 |
| Modal Pasaran | 1,811,825,408 |
| Harga / Jualan (P/S) | 914.87 |
| Harga / Buku (P/B) | 97.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 17 Mar 2025 |
| Margin Operasi (TTM) | -67,856.58% |
| EPS Cair (TTM) | -0.620 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.81% |
| Nisbah Semasa (MRQ) | 10.93 |
| Aliran Tunai Operasi (OCF TTM) | -126.35 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -121.36 M |
| Pulangan Atas Aset (ROA TTM) | -25.87% |
| Pulangan Atas Ekuiti (ROE TTM) | -41.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | ProKidney Corp. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 2.5 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -4.0 |
| Purata | 0.38 |
|
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 28.29% |
| % Dimiliki oleh Institusi | 44.35% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Mar 2025 | Pengumuman | ProKidney Reports Full Year 2024 Financial Results and Business Highlights |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |